JPMorgan raised the firm’s price target on Syndax (SNDX) to $39 from $35 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group post the Q4 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax price target lowered to $42 from $45 at Citi
- Promising Outlook for Syndax Pharmaceuticals: Buy Rating Supported by Revuforj Launch and Strategic Positioning
- Syndax Pharmaceuticals: Navigating Revenue Growth Amidst Regulatory and Market Challenges
- Syndax Pharmaceuticals Reports 2024 Financial Results
- Syndax Pharmaceuticals’ Earnings Call Highlights Key Milestones